Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 19/20 | 1.00 |
| ▸ | ABL1 | P00519 | 18/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 18/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 17/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 1.00 |
| ▸ | PRKDC | P78527 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | HCK | P08631 | 16/20 | 1.00 |
| ▸ | KDR | P35968 | 16/20 | 1.00 |
| ▸ | MTOR | P42345 | 16/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 16/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 16/20 | 1.00 |
| ▸ | BACE1 | P56817 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7508684 | 0.88 | SRC (0.78) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL14574603 | 0.86 | SRC (0.76) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL29390907 | 0.86 | SRC (0.98) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL14574629 | 0.86 | SRC (0.98) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL2468132 | 0.86 | SRC (1.00) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL12437092 | 0.85 | SRC (1.00) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL14574624 | 0.85 | SRC (0.74) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL29390196 | 0.85 | SRC (1.00) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL28897482 | 0.85 | SRC (0.82) | SRCABL1PIK3CDPIK3CGPIK3CB | |
| SCHEMBL3607897 | 0.85 | SRC (1.00) | SRCABL1PIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512125-B2 | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | US | disclosed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-05-14 | — | — | US | disclosed |
| US-7429596-B2 | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429596-B2 | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885PIK3CD 2019/4885 |
| US-20110144134-A1 | Anti-Inflammatory Pyrazolopyrimndines | TSLP, NLRP3, IL1B | SRC 3970/4885ABL1 2987/4885PIK3CD 3674/4885 |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885PIK3CD 2019/4885 |
| US-20090181988-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885PIK3CD 2019/4885 |
| US-20090124638-A1 | ANTI-INFLAMMATORY PYRAZOLOPYRIMIDINES | TNF, TSLP, IL1B | SRC 3920/4885ABL1 2533/4885PIK3CD 3413/4885 |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | SRC 2316/4885ABL1 3212/4885PIK3CD 2019/4885 |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | SRC 106/4885ABL1 53/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.